Redmile Group, LLC 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Redmile Group, LLC disclosed 40 US equity positions worth $1.0bn in its Q3 2025 13F filing. The largest position was SRRK at 14.1% of the reported book, followed by KRYS and STOK. Against the Q2 2025 filing, it opened 0 new positions, added to 4 and reduced 20 among the top 40 holdings.
What did Redmile Group, LLC own in Q3 2025? Top 40 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 14.1% | $145.4m | 3,904,456 | -1% | reduced |
| 2 | KRYS KRYSTAL BIOTECH INC | Healthcare | 11.4% | $116.8m | 661,388 | -0% | held |
| 3 | STOK STOKE THERAPEUTICS INC | Healthcare | 9.5% | $98.1m | 4,175,542 | -5% | reduced |
| 4 | ZYME ZYMEWORKS INC | Healthcare | 6.2% | $63.3m | 3,705,750 | -11% | reduced |
| 5 | ADCT ADC THERAPEUTICS SA | Healthcare | 6.1% | $62.7m | 15,666,731 | 0% | held |
| 6 | IMNM IMMUNOME INC | Healthcare | 5.7% | $58.8m | 5,023,385 | 3% | added |
| 7 | LIVN LIVANOVA PLC | Healthcare | 4.7% | $48.5m | 926,799 | -1% | reduced |
| 8 | RGNX REGENXBIO INC | Healthcare | 4.4% | $45.3m | 4,693,389 | -2% | reduced |
| 9 | AKERO THERAPEUTICS INC | 3.5% | $35.5m | 747,818 | -3% | reduced | |
| 10 | NRIX NURIX THERAPEUTICS INC | Healthcare | 3.3% | $34.0m | 3,678,394 | -1% | reduced |
| 11 | BEAM BEAM THERAPEUTICS INC | Healthcare | 3.3% | $33.7m | 1,387,559 | -3% | reduced |
| 12 | COGT COGENT BIOSCIENCES INC | Healthcare | 3.1% | $31.7m | 2,209,118 | 53% | added |
| 13 | ABSI ABSCI CORPORATION | 2.4% | $25.1m | 8,253,316 | 0% | held | |
| 14 | NGNE NEUROGENE INC | 2.2% | $22.5m | 1,299,022 | 2% | added | |
| 15 | ETNBGBP 89BIO INC | 2.1% | $21.7m | 1,473,136 | -5% | reduced | |
| 16 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 2.0% | $20.2m | 742,017 | 72% | added |
| 17 | ANNX ANNEXON INC | Healthcare | 1.9% | $19.2m | 6,300,644 | 0% | held |
| 18 | FATE FATE THERAPEUTICS INC | Healthcare | 1.6% | $16.2m | 12,872,946 | 0% | held |
| 19 | RAPT RAPT THERAPEUTICS INC | 1.4% | $14.3m | 552,594 | -12% | reduced | |
| 20 | STTK SHATTUCK LABS INC | Healthcare | 1.3% | $13.2m | 5,539,724 | 0% | held |
| 21 | SLDB SOLID BIOSCIENCES INC | Healthcare | 1.1% | $11.7m | 1,899,342 | -1% | reduced |
| 22 | SLN SILENCE THERAPEUTICS PLC | 1.1% | $11.2m | 2,164,777 | 0% | held | |
| 23 | NUVB NUVATION BIO INC | Healthcare | 1.1% | $11.2m | 3,031,009 | 0% | held |
| 24 | KROS KEROS THERAPEUTICS INC | Healthcare | 0.9% | $8.7m | 552,506 | 0% | held |
| 25 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 0.8% | $8.5m | 327,008 | -5% | reduced |
| 26 | ATRA ATARA BIOTHERAPEUTICS INC | 0.6% | $6.3m | 441,701 | 0% | held | |
| 27 | AM6 AMICUS THERAPEUTICS INC | 0.6% | $6.1m | 777,178 | -35% | reduced | |
| 28 | ALXO ALX ONCOLOGY HLDGS INC | Healthcare | 0.6% | $6.1m | 3,332,983 | -2% | reduced |
| 29 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 0.5% | $5.3m | 129,364 | -5% | reduced |
| 30 | CBLL CERIBELL INC | 0.5% | $5.0m | 435,239 | 0% | held | |
| 31 | XERS XERIS BIOPHARMA HOLDINGS INC | Healthcare | 0.4% | $3.7m | 451,099 | 0% | held |
| 32 | VTYXUSD VENTYX BIOSCIENCES INC | 0.3% | $3.3m | 1,073,386 | -4% | reduced | |
| 33 | LAVA THERAPEUTICS NV | 0.3% | $3.2m | 2,074,372 | 0% | held | |
| 34 | RPTX REPARE THERAPEUTICS INC | 0.3% | $2.8m | 1,586,174 | 0% | held | |
| 35 | IVVD INVIVYD INC | Healthcare | 0.2% | $2.5m | 2,285,320 | 0% | held |
| 36 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 0.2% | $2.4m | 1,591,695 | -3% | reduced |
| 37 | REPL REPLIMUNE GROUP INC | Healthcare | 0.2% | $2.2m | 535,818 | -89% | reduced |
| 38 | PRME PRIME MEDICINE INC | 0.0% | $482.6k | 87,118 | -96% | reduced | |
| 39 | KLRS KALARIS THERAPEUTICS INC | 0.0% | $479.5k | 82,955 | 0% | held | |
| 40 | BOLD BOUNDLESS BIO INC | 0.0% | $301.9k | 245,458 | -58% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.